Cancer imaging and treatment
A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [(P1-S1 j ) p -L-(S2 q -P2) r ] t wherein: P1 and P2, which may be the same or different, are cyclic oligopeptide moieties, at least one of P1 and P2 having the motif B-Arg or B-(Me) Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine or a derivative thereof; S1 and S2 are spacer groups, which may be the same or different; L is a linker moiety containing at least two functional groups for attachment of the cyclic oligopeptides or spacer groups; n and q are independently 0 or 1; p and r are independently integers of 1 or more; and t is an integer of 1 or more, provided that, when t, p or r is greater than 1, the cyclic oligopeptide moiety, spacer group and/or the value of j or q may be the same or different between the multiple (P1-S1 j ) moieties or multiple (S2 q -P2) moieties.
1. A compound, or a pharmaceutically acceptable salt or ester thereof, comprising the structure:
[(P1-S1 j ) p -L-(S2 q -P2) r ] t
wherein:
P1 and P2, which may be the same or different, are cyclic oligopeptide moieties, at least one of P1 and P2 having the motif B-Arg or B-(Me)Arg within the cyclic moiety, wherein B is an Nα-methyl derivative of a basic amino acid, or an N α -methyl derivative of phenylalanine;
S1 and S2 are spacer groups, which may be the same or different;
L is a linker moiety containing at least two functional groups for attachment of the cyclic oliqopeptides or spacer groups;
j and q are independently 0 or 1;
p and r are independently integers of 1 or more; and
t is an integer of 1 or more,
provided that, when t, p or r is greater than 1, the cyclic oliqopeptide moiety, spacer group and/or the value of j or q may be the same or different between the multiple (P1-S1 j ) moieties or multiple (S2 q -P2) moieties.
2. A compound, or a pharmaceutically acceptable salt or ester thereof, comprising the structure:
[(P1-S1 j ) p -L-(S2 q -P2) r ] t
wherein:
S1 and S2 are spacer groups, which may be the same or different;
L is a linker moiety containing at least two functional groups for attachment of the cyclic oliqopeptides or spacer groups;
j and q are independently 0 or 1;
p and r are independently integers of 1 or more; and
t is an integer of 1 or more,
P1 and P2, which may be the same or different, are cyclic oliqopeptide moieties, at least one of P1 and P2 is selected from cyclic oligopeptides having the sequence:
cyclo[ D -Tyr/(Me) D -Tyr-B-Arg/(Me)Arg-Z-(Ala) n -X]
wherein B is Orn or D-Orn, the ornithine residue being substituted at N α with one or two groups selected from fluorobenzoyl (FB), fluoropropionyl (FP), acetyl (Ac), amido (Am), Me, 1-naphthylmethyl (N1), 2-naphthylmethyl (N2), benzyl (Bz) and acyl spacer moieties, wherein the acyl spacer moiety is an acyl group containing a chain of 1-14 carbons, optionally interrupted by heteroatoms, and having a nucleophilic functional group at its end distal to the ornithine N α ;
Z is an amino acid containing an aromatic group in its side chain;
n is 1 or 0, provided that n is 1 only when the preceding four amino acids in the cyclic moiety sequence are D -Tyr/(Me)- D -Tyr-Arq-Arq-Nal, Nal being L -3-(2-naphthyl)alanine; and
X is selected from Gly, (Me)Gly, Ala, Dap (diaminopropionic acid), Dap(FP) ((N-fluoropropionyl)-diaminopropionic acid), Dab (diaminobutyric acid), Dab(FP) ((N-fluoropropionyl)-diaminobutyric acid), Dab(FB) ((N-fluorobenzoyl)-diaminobutyric acid) and Dap(FB) ((N-fluorobenzoyl)-diaminopropionic acid);
provided that, when t, p or r is greater than 1, the cyclic oligopeptide moiety, spacer group and/or the value of j or q may be the same or different between the multiple (P1-S1 j ) moieties or multiple (S2 g -P2) moieties.